LAPSE:2024.1547
Published Article

LAPSE:2024.1547
Modeling hiPSC-to-Early Cardiomyocyte Differentiation Process using Microsimulation and Markov Chain Models
August 16, 2024. Originally submitted on July 9, 2024
Abstract
Cardiomyocytes (CMs), the contractile heart cells that can be derived from human induced pluripotent stem cells (hiPSCs). These hiPSC derived CMs can be used for cardiovascular disease drug testing and regeneration therapies, and they have therapeutic potential. Currently, hiPSC-CM differentiation cannot yet be controlled to yield specific heart cell subtypes consistently. Designing differentiation processes to consistently direct differentiation to specific heart cells is important to realize the full therapeutic potential of hiPSC-CMs. A model that accurately represents the dynamic changes in cell populations from hiPSCs to CMs over the differentiation timeline is a first step towards designing processes for directing differentiation. This paper introduces a microsimulation model for studying temporal changes in the hiPSC-to-early CM differentiation. The differentiation process for each cell in the microsimulation model is represented by a Markov chain model (MCM). The MCM includes cell subtypes representing key developmental stages in hiPSC differentiation to early CMs. These stages include pluripotent stem cells, early primitive streak, late primitive streak, mesodermal progenitors, early cardiac progenitors, late cardiac progenitors, and early CMs. The time taken by a cell to transit from one state to the next state is assumed to be exponentially distributed. The transition probabilities of the Markov chain process and the mean duration parameter of the exponential distribution were estimated using Bayesian optimization. The results predicted by the MCM agree with the data.
Cardiomyocytes (CMs), the contractile heart cells that can be derived from human induced pluripotent stem cells (hiPSCs). These hiPSC derived CMs can be used for cardiovascular disease drug testing and regeneration therapies, and they have therapeutic potential. Currently, hiPSC-CM differentiation cannot yet be controlled to yield specific heart cell subtypes consistently. Designing differentiation processes to consistently direct differentiation to specific heart cells is important to realize the full therapeutic potential of hiPSC-CMs. A model that accurately represents the dynamic changes in cell populations from hiPSCs to CMs over the differentiation timeline is a first step towards designing processes for directing differentiation. This paper introduces a microsimulation model for studying temporal changes in the hiPSC-to-early CM differentiation. The differentiation process for each cell in the microsimulation model is represented by a Markov chain model (MCM). The MCM includes cell subtypes representing key developmental stages in hiPSC differentiation to early CMs. These stages include pluripotent stem cells, early primitive streak, late primitive streak, mesodermal progenitors, early cardiac progenitors, late cardiac progenitors, and early CMs. The time taken by a cell to transit from one state to the next state is assumed to be exponentially distributed. The transition probabilities of the Markov chain process and the mean duration parameter of the exponential distribution were estimated using Bayesian optimization. The results predicted by the MCM agree with the data.
Record ID
Keywords
Biosystems, Derivative-free optimization, hiPSC cardiac differentiation, Process Design
Subject
Suggested Citation
Rajendiran S, Galdos F, Lee CA, Xu S, Harvell J, Singh S, Wu SM, Lipke EA, Cremaschi S. Modeling hiPSC-to-Early Cardiomyocyte Differentiation Process using Microsimulation and Markov Chain Models. Systems and Control Transactions 3:344-350 (2024) https://doi.org/10.69997/sct.152564
Author Affiliations
Rajendiran S: Department of Chemical Engineering, Auburn University, Auburn, Alabama, USA
Galdos F: Stanford Cardiovascular Institute, Stanford Medicine, Stanford, California, USA
Lee CA: Stanford Cardiovascular Institute, Stanford Medicine, Stanford, California, USA
Xu S: Stanford Cardiovascular Institute, Stanford Medicine, Stanford, California, USA
Harvell J: Department of Chemical Engineering, Auburn University, Auburn, Alabama, USA
Singh S: Department of Chemical Engineering, Auburn University, Auburn, Alabama, USA
Wu SM: Stanford Cardiovascular Institute, Stanford Medicine, Stanford, California, USA
Lipke EA: Department of Chemical Engineering, Auburn University, Auburn, Alabama, USA
Cremaschi S: Department of Chemical Engineering, Auburn University, Auburn, Alabama, USA
Galdos F: Stanford Cardiovascular Institute, Stanford Medicine, Stanford, California, USA
Lee CA: Stanford Cardiovascular Institute, Stanford Medicine, Stanford, California, USA
Xu S: Stanford Cardiovascular Institute, Stanford Medicine, Stanford, California, USA
Harvell J: Department of Chemical Engineering, Auburn University, Auburn, Alabama, USA
Singh S: Department of Chemical Engineering, Auburn University, Auburn, Alabama, USA
Wu SM: Stanford Cardiovascular Institute, Stanford Medicine, Stanford, California, USA
Lipke EA: Department of Chemical Engineering, Auburn University, Auburn, Alabama, USA
Cremaschi S: Department of Chemical Engineering, Auburn University, Auburn, Alabama, USA
Journal Name
Systems and Control Transactions
Volume
3
First Page
344
Last Page
350
Year
2024
Publication Date
2024-07-10
Version Comments
DOI Assigned
Other Meta
PII: 0344-0350-676908-SCT-3-2024, Publication Type: Journal Article
Record Map
Published Article

LAPSE:2024.1547
This Record
External Link

https://doi.org/10.69997/sct.152564
Article DOI
Download
Meta
Links to Related Works
(0.08 seconds)
[0.09 s]


